Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Annovis Bio, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Annovis Bio (ANVS), AbbVie (ABBV) and Glaukos (GKOS)...

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) ...

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

Annovis Bio Inc ($ANVS) announced an update on their ongoing clinical study. Annovis Bio Inc. has launched a new study focused on long term safety ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ANVS	$1.15	+4.09%	467.77K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ANVS	$1.15	+4.1%	467.77K
3
4
5
6

ANVS

Get Annovis Bio, Inc. Data in Excel

Get Annovis Bio, Inc. Data in Excel